EQL Pharma AB's total inventories for the quarter that ended in Mar. 2026 was kr200.5 Mil. EQL Pharma AB's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was kr198.6 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. EQL Pharma AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was kr-11.08.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
EQL Pharma AB's Days Inventory for the
three
months ended in Mar. 2026 was 210.29.
Inventory Turnover measures how fast the company turns over its inventory within a year.
EQL Pharma AB's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.43.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
EQL Pharma AB's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.65.
EQL Pharma AB (OSTO:EQL) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
EQL Pharma AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
EQL Pharma AB's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
EQL Pharma AB Total Inventories Related Terms
EQL Pharma AB Total Inventories Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of kr200.5 Mil mean?
EQL Pharma AB (OSTO:EQL) has a Total Inventories of kr200.5 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for EQL Pharma AB and its competitors.
Is EQL Pharma AB's Total Inventories too high?
EQL Pharma AB's current Total Inventories is kr200.5 Mil. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Total Inventories compare to ZTS and UTHR?
EQL Pharma AB's Total Inventories of kr200.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for EQL Pharma AB and its competitors. EQL Pharma AB's current Total Inventories is kr200.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Total Inventories of kr200.5 Mil. The current Total Inventories is kr200.5 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Total Inventories is kr200.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
